Wearable AI-Powered Neurotech Startup Promises 'Electric Medicine' and Wellness Benefits - Slashdot

"Something revolutionary is on the horizon..." claims the company's web site. "Wearable neurotechnology that augments sleep, attention, and ultimately the human experience."

Or, as Fierce Biotech put it, "A startup emerged from stealth this week with grand plans to pioneer a new form of neurotech dubbed 'electric medicine.'" Elemind's approach centers on artificial intelligence-powered algorithms that are trained to continuously analyze neurological activity collected by a noninvasive wearable device, then to deliver through the wearable bursts of neurostimulation that are uniquely tailored to those real-time brain wave readings. The Cambridge, Massachusetts-based company claims that its approach — which is based on research from its founders, a group of high-profile scientists hailing from the likes of MIT, Stanford and Harvard — offers a more "natural" treatment option than pharmaceuticals for neurological conditions like insomnia, essential tremor and memory loss.

"Chemical drugs affect the entire body, often leading to unwanted side effects. Elemind offers a nonchemical, direct and on-demand solution that learns and dynamically adjusts to each person," Meredith Perry, a co-founder of Elemind and its CEO, said in the company's debut announcement. "We're the first and only company able to precisely guide and redirect brainwaves in real time."

"Elemind's first product is a general wellness device and will not be subject to FDA regulation," notes an announcement from the company. But they've thoroughly researched the product's potential: To date, Elemind's technology is supported by five clinical trials and several publications in peer-reviewed scientific journals. Clinical trials show Elemind's technology is effective at inducing sleep up to 74% faster, suppressing essential tremor with a significant decrease after only 30 seconds of stimulation, and boosting memory. Clinical trials also demonstrate Elemind is effective at increasing pain thresholds and enhancing sedation; this study is currently in peer review....

"You can think about it like noise cancellation for the mind," said Dr. David Wang, CTO and co-founder of Elemind. "Our technology uses phase-locking auditory stimuli to align precisely with the user's brainwaves and steer them to a different frequency associated with a different state."

The company plans to announce its first product within a few months, reports the Boston Globe, noting that the company's $12 million in seed funding came from "a consortium that includes Village Global, an early-stage venture fund backed by high-tech billionaires Jeff Bezos, Bill Gates., Reid Hoffman, and Ann Wojcicki..."

More info from VentureBeat.